NanoenTekInc (039860) - Cash Flow Conversion Efficiency
Based on the latest financial reports, NanoenTekInc (039860) has a cash flow conversion efficiency ratio of 0.031x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩2.26 Billion ≈ $1.53 Million USD) by net assets (₩73.19 Billion ≈ $49.60 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
NanoenTekInc - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how NanoenTekInc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read NanoenTekInc debt and liabilities for a breakdown of total debt and financial obligations.
NanoenTekInc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NanoenTekInc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sakar Healthcare Limited
NSE:SAKAR
|
0.101x |
|
Om Holdings Ltd
AU:OMH
|
-0.146x |
|
Fiamma Holdings Bhd
KLSE:6939
|
-0.039x |
|
PPX Mining Corp
V:PPX
|
0.614x |
|
KJTS
KLSE:0293
|
0.018x |
|
United Paper Public Company Limited
BK:UTP
|
0.036x |
|
HomesToLife Ltd
NASDAQ:HTLM
|
0.288x |
|
EQL PHARMA AB
F:7JK
|
0.050x |
Annual Cash Flow Conversion Efficiency for NanoenTekInc (2013–2024)
The table below shows the annual cash flow conversion efficiency of NanoenTekInc from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see 039860 market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩73.99 Billion ≈ $50.15 Million |
₩-2.46 Billion ≈ $-1.67 Million |
-0.033x | -175.79% |
| 2023-12-31 | ₩53.59 Billion ≈ $36.32 Million |
₩-645.79 Million ≈ $-437.64K |
-0.012x | -108.64% |
| 2022-12-31 | ₩57.65 Billion ≈ $39.07 Million |
₩8.04 Billion ≈ $5.45 Million |
0.140x | -21.38% |
| 2021-12-31 | ₩52.34 Billion ≈ $35.47 Million |
₩9.29 Billion ≈ $6.30 Million |
0.177x | +41.71% |
| 2020-12-31 | ₩45.49 Billion ≈ $30.83 Million |
₩5.70 Billion ≈ $3.86 Million |
0.125x | +25.86% |
| 2019-12-31 | ₩41.03 Billion ≈ $27.80 Million |
₩4.08 Billion ≈ $2.77 Million |
0.100x | +131.90% |
| 2018-12-31 | ₩35.15 Billion ≈ $23.82 Million |
₩1.51 Billion ≈ $1.02 Million |
0.043x | -40.33% |
| 2017-12-31 | ₩23.73 Billion ≈ $16.08 Million |
₩1.71 Billion ≈ $1.16 Million |
0.072x | +160.86% |
| 2016-12-31 | ₩25.58 Billion ≈ $17.33 Million |
₩-3.02 Billion ≈ $-2.05 Million |
-0.118x | -28.30% |
| 2015-12-31 | ₩38.41 Billion ≈ $26.03 Million |
₩-3.54 Billion ≈ $-2.40 Million |
-0.092x | -100.69% |
| 2014-12-31 | ₩35.50 Billion ≈ $24.06 Million |
₩-1.63 Billion ≈ $-1.10 Million |
-0.046x | -152.33% |
| 2013-12-31 | ₩23.58 Billion ≈ $15.98 Million |
₩2.07 Billion ≈ $1.40 Million |
0.088x | -- |
About NanoenTekInc
NanoEntek, Inc. engages in the research and development, production, and sale of life-science lab equipment, in vitro diagnostic medical devices, point of care diagnostic devices, and related consumables and solutions in Korea and internationally. It provides FREND system, a fluorescence immunoassay analyzer; BUDDI, a rapid diagnostic test analyzer; rapid diagnostic test items; ADAM-rWBC, a resid… Read more